EVAX
What one share of Evaxion A/S holds
Biological Products, (No Diagnostic Substances)
Evaxion A/S’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $1.18 |
|---|---|
| Profit | −$1.21 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.03 |
| Cash and investments | $2.79 |
| Debt | $0.67 |
| Book value | $2.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$21.43 | $0.03 | −$7.74 | — | −$3.60 |
| 2019 | — | −$40.29 | $0.22 | −$25.48 | — | $33.70 |
| 2020 | — | −$48.65 | $0.48 | −$40.77 | — | $21.73 |
| 2021 | — | −$62.92 | $3.33 | −$59.59 | — | $69.89 |
| 2022 | $0.00 | −$49.01 | $0.62 | −$55.13 | — | $17.20 |
| 2023 | $0.14 | −$40.47 | $0.16 | −$32.52 | — | −$6.24 |
| 2024 | $3.12 | −$9.85 | $0.00 | −$12.06 | — | −$1.18 |
| 2025 | $1.18 | −$1.21 | $0.00 | −$1.03 | — | $2.04 |